Literature DB >> 29398800

Role of BAALC Gene in Prognosis of Acute Lymphoblastic Leukemia in Egyptian Children.

Adel A Hagag1, Walid A Elshehaby1, Nahd M Hablas1, Mohamed M Abdelmageed1, Amal Ezzat Abd El-Lateef2.   

Abstract

Acute lymphoblastic leukemia (ALL) is characterized by excess bone marrow lymphoblast cell production. Brain and Acute Leukemia Cytoplasmic gene (BAALC gene) is a recently identified gene on chromosome 8q22.3. The aim of this work was to study the role of BAALC gene in prognosis of ALL in Egyptian children. This study was conducted on 60 children with ALL who were admitted in Oncology Unit in the period from January 2012 to March 2015 including 36 males and 24 females with mean age of 8.74 ± 2.66 years. For all patients the following were done: Full history taking, thorough clinical examination and laboratory investigations including: complete blood count, LDH, bone marrow aspiration, cytochemistry, immunophenotyping, FISH technique for detection of t(12;21) and t(9;22) and assessment of BAALC gene expression by PCR in bone marrow aspirate mononuclear cells at diagnosis before chemotherapy. Positive BAALC gene expression was found in 36 patients (60%) and negative expression in 24 patients (40%). Positive BAALC gene expression group includes 14 males and 22 females with mean age at presentation of 8.45 ± 2.77 years while negative BAALC gene expression group includes 18 males and 6 females with mean age at presentation of 8.61 ± 2.44 years with no significant differences between positive and negative BAALC gene expression groups regarding age, sex, clinical presentations, WBCs and platelets counts, hemoglobin and LDH levels, peripheral blood and BM blast cell counts, immunophenotyping and chromosomal translocations including t(12;21) and t(9;22). There were significant differences in disease outcome between positive and negative BAALC gene expression groups with higher rate of relapse and death and lower rate of complete remission, disease free survival (DFS) and overall survival (OS) in positive BAALC gene expression group compared with negative group (p = 0.028). Multivariate analyses for overall survival and disease free survival shows significant role of BAALC gene expression in OS and DFS. BAALC expression might represent an additional prognostic marker in children with ALL and should be routinely assessed at diagnosis for better prognostic assessment.

Entities:  

Keywords:  Acute lymphoblastic leukemia (ALL); BAALC gene expression; Prognostic factors of ALL

Year:  2017        PMID: 29398800      PMCID: PMC5786634          DOI: 10.1007/s12288-017-0841-9

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  24 in total

1.  Prognostic implication of BAALC gene expression in adult acute myeloid leukemia.

Authors:  Raida S Yahya; Mamdouh A Sofan; Hanaa M Abdelmasseih; Niveen Saudy; Mohamed A Sharaf-Eldein
Journal:  Clin Lab       Date:  2013       Impact factor: 1.138

2.  Prognostic significance of the BAALC gene expression in adult patients with acute myeloid leukemia: A meta-analysis.

Authors:  Shi-Ji Xiao; Jian-Zhen Shen; Jin-Long Huang; Hai-Ying Fu
Journal:  Mol Clin Oncol       Date:  2015-05-11

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia.

Authors:  S M Tanner; J L Austin; G Leone; L J Rush; C Plass; K Heinonen; K Mrózek; H Sill; S Knuutila; J E Kolitz; K J Archer; M A Caligiuri; C D Bloomfield; A de La Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

5.  Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.

Authors:  John M Goldberg; Lewis B Silverman; Donna E Levy; Virginia Kimball Dalton; Richard D Gelber; Leslie Lehmann; Harvey J Cohen; Stephen E Sallan; Barbara L Asselin
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

6.  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Nita L Seibel; Peter G Steinherz; Harland N Sather; James B Nachman; Cynthia Delaat; Lawrence J Ettinger; David R Freyer; Leonard A Mattano; Caroline A Hastings; Charles M Rubin; Kathy Bertolone; Janet L Franklin; Nyla A Heerema; Torrey L Mitchell; Allan F Pyesmany; Mei K La; Cheryl Edens; Paul S Gaynon
Journal:  Blood       Date:  2007-11-26       Impact factor: 22.113

7.  BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

Authors:  Claudia D Baldus; Stephan M Tanner; Amy S Ruppert; Susan P Whitman; Kellie J Archer; Guido Marcucci; Michael A Caligiuri; Andrew J Carroll; James W Vardiman; Bayard L Powell; Steven L Allen; Joseph O Moore; Richard A Larson; Jonathan E Kolitz; Albert de la Chapelle; Clara D Bloomfield
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

8.  Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.

Authors:  Claudia D Baldus; Peter Martus; Thomas Burmeister; Stefan Schwartz; Nicola Gökbuget; Clara D Bloomfield; Dieter Hoelzer; Eckhard Thiel; Wolf K Hofmann
Journal:  J Clin Oncol       Date:  2007-07-23       Impact factor: 44.544

9.  Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.

Authors:  Allen R Chauvenet; Paul L Martin; Meenakshi Devidas; Stephen B Linda; Beverly A Bell; Joanne Kurtzberg; Jeanette Pullen; Mark J Pettenati; Andrew J Carroll; Jonathan J Shuster; Bruce Camitta
Journal:  Blood       Date:  2007-04-18       Impact factor: 22.113

Review 10.  Current management and challenges of malignant disease in the CNS in paediatric leukaemia.

Authors:  Ching-Hon Pui; Scott C Howard
Journal:  Lancet Oncol       Date:  2008-03       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.